Topics

Entasis Therapeutics Holdings Inc. Company Profile

13:33 EDT 21st September 2019 | BioPortfolio

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), a Non-Beta-lactam PBP inhibitor (targeting Gram-negative infections), and zoliflodacin (targeting Neisseria gonorrhoeae). www.entasistx.com


News Articles [1492 Associated News Articles listed on BioPortfolio]

Entasis begins Phase III trial to address Acinetobacter infections

Entasis Therapeutics has initiated the pivotal Phase III ATTACK clinical trial of ETX2514SUL to treat pneumonia and bloodstream infections caused...Read More... The post Entasis begins Phase III trial...

Entasis Therapeutics Appoints Dr. Howard Mayer to Board of Directors

WALTHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ant...

Entasis Therapeutics Appoints David Meek as Chairman of the Board

WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ant...

Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ant...

Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results

WALTHAM, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug...

Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel

WALTHAM, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel an...

Entasis Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference

WALTHAM, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ant...

Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

WALTHAM, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel an...

PubMed Articles [448 Associated PubMed Articles listed on BioPortfolio]

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Spreading dynamics in a cattle trade network: Size, speed, typical profile and consequences on epidemic control strategies.

Infections can spread among livestock notably because infected animals can be brought to uncontaminated holdings, therefore exposing a new group of susceptible animals to the disease. As a consequence...

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Clinical Trials [191 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1867 Associated Companies listed on BioPortfolio]

Entasis Therapeutics Holdings Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patie...

Entasis Therapeutics Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patie...

Auven Therapeutics

Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. ...

Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on serving the needs of the pediatric marketplace. Commercially-proven branded product f...

InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in in...

More Information about "Entasis Therapeutics Holdings Inc." on BioPortfolio

We have published hundreds of Entasis Therapeutics Holdings Inc. news stories on BioPortfolio along with dozens of Entasis Therapeutics Holdings Inc. Clinical Trials and PubMed Articles about Entasis Therapeutics Holdings Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Entasis Therapeutics Holdings Inc. Companies in our database. You can also find out about relevant Entasis Therapeutics Holdings Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record